Feline amphiregulin (AREG) is a member of the epidermal growth factor (EGF) family and functions as a ligand for the epidermal growth factor receptor (EGFR/ErbB1), where it regulates epithelial cell proliferation, differentiation, tissue repair, and inflammatory responses. In cats (Felis catus), amphiregulin is produced by epithelial cells, fibroblasts, keratinocytes, and activated immune cells including T lymphocytes and mast cells, particularly in response to tissue injury, allergen exposure, and inflammatory cytokines. Through activation of EGFR signaling pathways, amphiregulin contributes to wound healing, mucosal barrier maintenance, and remodeling of epithelial tissues, but dysregulated expression may also promote chronic inflammation, fibrosis, or tumor progression. In veterinary and comparative medicine research, feline amphiregulin is of interest in studies of allergic skin disease (e.g., atopic dermatitis), asthma, inflammatory bowel disease, wound repair, and neoplastic conditions such as squamous cell carcinoma and mammary carcinoma, where EGFR-driven signaling plays a role. Understanding amphiregulin expression and function in cats provides insight into epithelial–immune crosstalk, tissue remodeling processes, and potential therapeutic targets in both veterinary and translational oncology and inflammatory disease research.